What is graft-versus-host-disease and who is most at risk?

Each year, thousands of patients with hematologic malignancies undergo allogeneic stem cell transplantation (that is, they receive a donor’s stem cells), offering them a chance at cure.

Graft-versus-host disease is a potentially deadly complication of this therapy and occurs in approximately 25 to 60 percent of patients.

Jonathan Cotliar, MD is here to discuss graft-versus-host-disease, why it occurs and it's treatment and symptoms.